Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research "Fragment-based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023", the global fragment-based drug discovery market was valued at USD 0.4 billion in 2014 and is projected to expand at a CAGR of 14.4% from 2015 to 2023 to reach USD 1.2 billion in 2023.
Browse Market Research Report on Fragment-based Drug Discovery Market:
http://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html
The assurance of logical and efficient lead innovation has fuelled interest for fragment-based drug discovery (FBDD). This enthusiasm is further complemented by a paradigm shift from conventional techniques like high-throughput screening (HTS) towards design intensive approaches, enabled by computational and structural biology. Fragment-based drug discovery utilizes comparatively small libraries of "fragments or ligands" that are of low-molecular weights. These fragments are evaluated for binding affinity, then incrementally altered into more potent molecules against the biological target(s) of interest. The major advantages of this technique that are expected to drive the popularity of FBDD among pharmaceutical companies are less cost and time process, streamlined equipment operability, and higher success rates of hits.
Get Sample Report Copy of Fragment-based Drug Discovery Market:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4741
Major factors likely to boost the growth of the market are Simpler and less time consuming technique, streamlining and easy access to advanced biophysical techniques could drive the market in the near future. However, lower level of potency in few of the compounds derived from fragment screening and requirement of high protein and unique fragment library to conduct studies would hamper the growth of the fragment-based drug discovery market during the forecast period.
Fragment screening services and fragment optimization collectively form the fragment-based drug discovery market. Fragment screening segment was further segmented into biophysical services and non-biophysical services. Biophysical services are further segmented into techniques such as Nuclear Magnetic Resonance (NMR) Spectroscopy, Differential scanning Fluorimetry (DSF) Assay (Thermal Shift), Fluorescence Polarization (FP), Isothermal Titration Calorimetry (ITC), X-ray Crystallography, Surface Plasmon Resonance, Biolayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, and others (biochemical assays). NMR was the largest segment of the FBDD market, accounting for approximately 19.7% share in 2014. The technique is expected to maintain its leadership position during the forecast period. Advantages of NMR such as high reliability, easy operability, and wide versatility are likely to fuel the growth of the NMR segment. However, high procurement cost and availability of cheaper alternatives could hamper market growth.
Demand for fragment-based drug discovery is increasing in pharmaceutical companies, CROs, and academic & research institutions as these procedures detect fragments with low affinity binding which is generally difficult to detect by most other methods. Based on end-users the FBDD market has been segmented into biopharmaceutical companies, CROs, and academic and research institutions. Among these, biopharmaceutical companies emerged as the major FBDD service user, accounting for 46.0% in 2014. Low productivity, dwindling pipeline, and rising R&D costs are inducing biopharmaceutical companies to narrow down the gaps in the current drug discovery processes, thereby boosting productivity and implementation of FBDD as drug discovery technique.
Key organizations studied and profiled in this report include Astex Pharmaceuticals, Alveus Pharmaceuticals Pvt. Ltd., Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Inc., Evotec AG, Kinetic Discovery Limited, Proteros Fragments GmbH, Sprint Bioscience, Structure Based Design, Inc., Sygnature Discovery. These players also collaborate with biopharmaceutical companies, and CROs through long-term agreements in order to provide fragment-based services for drug discovery. This, in turn, helps them to strengthen their market position and subsequently experience rapid growth.
Browse Upcoming Market Research Reports:-
- Computational Biology Market: http://www.transparencymarketresearch.com/computational-biology.html
- DNA Sequencing In Drug Discovery Market: http://www.transparencymarketresearch.com/dna-sequencing-drug-discovery-market.html
- Drug Discovery Technologies Market: http://www.transparencymarketresearch.com/drug-discovery-technologies.html
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.